Collegium Pharmaceutical: Q3 Earnings Snapshot

Collegium Pharmaceutical (COLL) reported Q3 net income of $21.8M, or 60 cents per share, with adjusted EPS of $1.96. Revenue was $216.3M, exceeding analyst estimates of $1.77 EPS and $215M revenue, according to Zacks.

Original reporting
Published Nov 5, 2026, 12:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Collegium Pharmaceutical: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$COLLBullishMed
01

Why it matters

Earnings beat could trigger short-covering and new buying, especially from investors tracking biotech earnings beats.

02

Market read

First-report earnings beat for COLL provides a fresh catalyst for short-term trading.

03

What to watch

Guidance outlook and pipeline updates were not disclosed.

Relevance 7/10Novelty 8/10Timing: after-hours reaction

Background

Collegium Pharmaceutical (COLL) is a specialty pharma company focused on rare diseases.

Company-level read

Ticker impact

$COLLBullishHigh confidence
Context

Collegium Pharmaceutical reported Q3 net income of $21.8M, EPS $0.60 and revenue $216.3M, both beating Zacks estimates.

Expected impact

likely upside as investors price in the earnings beat.

Evidence & confidence

The beat exceeds consensus estimates, which typically drives short-term buying pressure.

Market effects

Positive earnings may lift other specialty pharma peers.

Limited to US biotech/ pharma sector.

Modest, confined to niche biotech investors.

Counterpoint

Beat may be priced in quickly, limiting upside.

Key entities

  • Collegium Pharmaceutical Inc.

    Specialty pharmaceutical firm reporting Q3 results.

Related articles

$COLLMedAI 8/10

Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

$COLLMed

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

$COLLMed

Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

$COLLMed

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.

$COLLLow

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Genera